Novartis AG ADR (NVS)vsVerastem Inc (VSTM)
NVS
Novartis AG ADR
$137.16
+1.36%
HEALTHCARE · Cap: $260.70B
VSTM
Verastem Inc
$7.32
-3.94%
HEALTHCARE · Cap: $742.62M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 64673% more annual revenue ($56.69B vs $87.53M). NVS leads profitability with a 22.5% profit margin vs -231.6%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
VSTM
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Margin of Safety
+83.3%
Fair Value
$34.92
Current Price
$7.32
$27.60 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Revenue surging 1775.0% year-over-year
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Trading at 13.3x book value
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : VSTM
The strongest argument for VSTM centers on Revenue Growth. Revenue growth of 1775.0% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : VSTM
The primary concerns for VSTM are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 1.69 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS profiles as a value stock while VSTM is a hypergrowth play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
VSTM is growing revenue faster at 1775.0% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 28/100), backed by strong 22.5% margins. VSTM offers better value entry with a 83.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Verastem Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Verastem, Inc., a developing-stage biopharmaceutical company focused on developing and commercializing life-enhancing drugs for cancer patients. The company is headquartered in Needham, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?